
AECOS (American-European Congress of Ophthalmic Surgery)
🚀 Just wrapped up an incredible session at AECOS (American-European Congress of Ophthalmic Surgery) in London! and the response was electric ⚡ 🧠 From innovation
🚀 Just wrapped up an incredible session at AECOS (American-European Congress of Ophthalmic Surgery) in London! and the response was electric ⚡ 🧠 From innovation
As the American Society of Cataract and Refractive Surgery (ASCRS) meeting wraps up, sharing this beautiful moment captured at the event: A proud snapshot 📸featuring:
What began nearly 14 years ago as a bold idea—to rethink the way we treat corneal endothelial disease—has become a reality that’s now changing lives.
Today, we’re thrilled to celebrate a major milestone at EyeYon Medical: the 400th commercial implantation of EndoArt® since its launch in September 2023! This achievement
The study evaluates the long-term outcomes of the EndoArt artificial endothelial implant in patients with chronic corneal edema. Over two years, the device significantly improved
This 4.5-year follow-up study of the EndoArt corneal endothelial prosthesis showed 90% long-term adherence, significant reduction in central corneal thickness, and visual improvement in 60%
Detailed review and clinical insights into EndoArt use for chronic corneal oedema cases.
Retrospective findings on EndoArt effectiveness in GDD patients with high transplant failure risk.
Case demonstrating novel technique ensuring safe EndoArt placement in high-risk scenarios.
Short-term improvement in corneal clarity and reduced edema after EndoArt implantation.
Alternative implantation method reducing complications in severe endothelial dysfunction cases.
Promising outcomes in high-risk patients with complex ocular conditions using EndoArt.
Demonstrated safety and efficacy in treating chronic corneal edema across multi-center trials.
Alternative for patients experiencing multiple transplant failures and high rejection rates.
Improved outcomes post-EndoArt for repeat keratoplasty failure with limited complications.
Innovative method aiding EndoArt use in complex ocular conditions over 1-year follow-up.
Early human trials of the EndoArt artificial corneal implant show it to be safe and effective in reducing corneal thickness without adverse events over 12
Reports the first artificial corneal endothelial transplantation in China, demonstrating significant improvement in severe corneal edema.
Early trials of the EndoArt artificial endothelial implant, including Heidelberg’s 2-year follow-up, show promising safety and efficacy, making it a viable option for treating endothelial
Dutch eye surgeon Dr. Ruth Lapid-Gortzak collaborated with EyeYon Medical to test a synthetic corneal endothelial implant as a solution to donor shortages. A first
Implantation of an artificial endothelial layer (EndoArt®, EyeYon Medical) is a promising treatment for select eyes with chronic corneal oedema from corneal endothelial dysfunction, according
A novel artificial endothelial implant may provide a safe, efficient, and cost-effective treatment modality for chronic corneal oedema and dispense the need for donor tissue
Reviews current and emerging therapies for corneal endothelial regeneration, addressing the global tissue shortage and innovative treatments such as EndoArt. dysfunction.
EndoArt demonstrates potential as a synthetic solution for chronic corneal edema management.